ONCAlert | Upfront Therapy for mRCC
Videos  >  

Reviewing Key Points from the Phase III MURANO Trial in CLL

William G. Wierda, MD, PhD
Published Online:8:32 PM, Fri May 10, 2019

William G. Wierda, MD, PhD, professor in the department of leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the take home message from the phase III MURANO trial that identified venetoclax (Venclexta) plus rituximab (Rituxan) as a new treatment option for patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

There are patients with CLL that achieve a deep remission by the end of 2-year treatment. Wierda says this remission and progression-free survival can be maintained after patients come off treatment.

These data demonstrate that fixed duration treatment in the relapsed setting of CLL is a potential strategy for managing disease as opposed to putting patients on an indefinite and continuous treatment.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.